The immune tolerant phase of chronic HBV infection: New perspectives on an old concept

Cellular and Molecular Immunology

Volumn 12, Issue 3, 2015, Pages 258-263

  Bertoletti, Antonio ^a,b   Kennedy, Patrick T ^c  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

antiviral immunity; Hepatitis B; T cells

Indexed keywords

HEPATITIS B VACCINE;

AGE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; NONHUMAN; PERINATAL INFECTION; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION; ADULT; ANIMAL; CHILD; CHRONIC HEPATITIS B; DISEASE COURSE; IMMUNOLOGY; INFANT; LIVER; PHYSIOLOGY; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGE FACTORS; ANIMALS; CHILD; DISEASE PROGRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; INFANT; LIVER; VIRUS REPLICATION;

EID: 84928889426     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.79     Document Type: Review

References (52)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004; 11: 97-107.
2. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-S181.
3. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-6603.
4. D'Antiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G. Combined lamivudine/interferon-A treatment in 'immunotolerant' children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148: 228-233.e1.
5. Carey I, D'Antiga L, Bansal S, Longhi MS, Ma Y, Mesa IR et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virusinfected children on combined therapy. J Virol 2011; 85: 2416-2428.
6. Andrade BB, Santos CJ, Camargo LM, Souza-Neto SM, Reis-Filho A, Clarencio J et al. Hepatitis B infection is associated with asymptomatic malaria in the Brazilian Amazon. PLoS ONE 2011; 6: e19841.
7. Thursz MR, Kwiatkowski D, Torok ME, Allsopp CE, Greenwood BM, Whittle HC et al. Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. Nat Med 1995; 1: 374-375.
8. Kennedy PT, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT et al. Preserved T-cell function in children and young adults with immunetolerant chronic hepatitis B. Gastroenterology 2012; 143: 637-645.
9. Chang MH, Hwang LY, Hsu HC, Lee CY, Beasley RP. Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies. Hepatology 1988; 8: 374-377.
10. Hsu HC, Lin YH, Chang MH, Su IJ, Chen DS. Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens. Hepatology 1988; 8: 378-382.
11. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol 2012; 12: 636-648.
12. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764.
13. Publicover J, Gaggar A, Nishimura S, van Horn CM, Goodsell A, Muench MO et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 2013; 123: 3728-3739.
14. Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121: 1154-1162.
15. Mold JE, Venkatasubrahmanyam S, Burt TD, Michaelsson J, Rivera JM, Galkina SA et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 2010; 330: 1695-1699.
16. Zhang X, Mozeleski B, Lemoine S, Deriaud E, Lim A, Zhivaki D et al. CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus. Sci Transl Med 2014; 6: 238ra72-238ra72.
17. Marchant A, Appay V, van der Sande M, Dulphy N, Liesnard C, KiddM et al. Mature CD81 T lymphocyte response to viral infection during fetal life. J Clin Invest 2003; 111: 1747-1755.
18. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, van Rysselberge M et al. Human cytomegalovirus elicits fetal T cell responses in utero. J Exp Med 2010; 207: 807-821.
19. Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995; 154: 433-443.
20. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7: 379-390.
21. Komatsu H, Inui A, Sogo T, Hiejima E, Tateno A, Klenerman P et al. Cellular immunity in children with successful immunoprophylactic treatment for mother-To-child transmission of hepatitis B virus. BMC Infect Dis 2010; 10: 103.
22. Koumbi L, Bertoletti A, Anastasiadou V, Machaira M, Goh W, Papadopoulos NG et al. Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg1/HBeAg2 mothers. Cell Mol Immunol 2010; 7: 454-458.
23. Koumbi LJ, Papadopoulos NG, Anastassiadou V, Machaira M, Kafetzis DA, Papaevangelou V. Dendritic cells in uninfected infants born to hepatitis B virus-positive mothers. Clin Vaccine Immunol 2010; 17: 1079-1085.
24. Guo J, Gao Y, Guo Z, Zhang LR, Wang B, Wang SP. Frequencies of dendritic cells and Toll-like receptor 3 in neonates born to HBsAgpositive mothers with different HBV serological profiles. Epidemiol Infect 2014; in press.
25. Zheng Z, Chen D, Yao J, Zhang H, Jin L, Shi M et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol 2007; 122: 173-180.
26. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitisBimmuneglobulin and hepatitisBvaccine. Lancet 1983;2: 1099-1102.
27. Mackie CO, Buxton JA, Tadwalkar S, Patrick DM. Hepatitis B immunization strategies: timing is everything. Can Med Assoc J 2009; 180: 196-202.
28. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS et al. The role of virus-specific CD81 cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
29. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL et al. Longitudinal analysis of CD81 T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
30. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al. CD81 T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
31. Stabenow D, Frings M, Truck C, Gartner K, Forster I, Kurts C et al. Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology 2010; 51: 1430-1437.
32. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
33. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD81 T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2009; 184: 287-295.
34. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2011; 194: 1755-1766.
35. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-1554.
36. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004; 113: 1158-1167.
37. Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG. Depletion of neutrophils blocks the recruitment of antigennonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci USA 2002; 99: 13717-13722.
38. Wang HY, Chien MH, Huang HP, Chang HC, Wu CC, Chen PJ et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010; 84: 3454-3463.
39. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012; 61: 333-336.
40. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37: 771-783.
41. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol 2010; 22: 507-513.
42. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD41 T cells. J Exp Med 2001; 194: 1711-1719.
43. Fedson DS. Was bacterial pneumonia the predominant cause of death in the 1918-1919 influenza pandemic? J Infect Dis 2009; 199: 1408-1509; author reply 1409-1410.
44. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99: 417-435.
45. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52: 330-339.
46. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680.
47. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
48. Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T et al. Interleukin-1 and tumor necrosis factor-A trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem2013; 288: 31715-31727.
49. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81: 7351-7362.
50. Maini MK, Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol 2013; 4: 57.
51. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leuk Biol 2006; 81: 100-107.
52. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109: E2165-E2172.